Comparative Pharmacology of GP IIb/IIIa Antagonists (Q28166129)

Europe PubMed Central

title

Comparative pharmacology of GP IIb/IIIa antagonists (English)

0 references

Comparative Pharmacology of GP IIb/IIIa Antagonists (English)

1 reference

10.1023/B:THRO.0000003308.63022.8D

Crossref

DOI

https://api.crossref.org/works/10.1023/B:THRO.0000003308.63022.8D

2 April 2024

1 reference

Cardiology and cardiovascular medicine

1 reference

10.1023/B:THRO.0000003308.63022.8D

Crossref

DOI

https://api.crossref.org/works/10.1023/B:THRO.0000003308.63022.8D

Journal of Thrombosis and Thrombolysis

2 April 2024

author name string

Karsten Schrör

series ordinal

1

0 references

Artur-Aron Weber

series ordinal

2

0 references

language of work or name

English

0 references

publication date

April 2003

0 references

published in

0 references

volume

15

0 references

issue

2

0 references

page(s)

71-80

0 references

cites work

Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin

1 reference

12 December 2020

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

1 reference

12 December 2020

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects.

1 reference

12 December 2020

Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition

1 reference

12 December 2020

Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates

1 reference

12 December 2020

Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics

1 reference

12 December 2020

Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

1 reference

12 December 2020

Platelet GPIIb-IIIa blockers

1 reference

12 December 2020

7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

1 reference

12 December 2020

Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins

1 reference

12 December 2020

Paradoxical platelet activation was not observed on dissociation of abciximab from GpIIb-IIIa complexes.

1 reference

12 December 2020

Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors

1 reference

12 December 2020

Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport

1 reference

12 December 2020

Tirofiban. A review of its use in acute coronary syndromes

1 reference

12 December 2020

Glycoprotein IIIa Pl(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly

1 reference

12 December 2020

Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells

1 reference

12 December 2020

Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial

1 reference

12 December 2020

Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban

1 reference

12 December 2020

Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes

1 reference

12 December 2020

Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation

1 reference

12 December 2020

AlphaIIbbeta3 and its antagonism at the new millennium

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?

1 reference

12 December 2020

Evaluation of platelet membrane glycoproteins in coronary artery disease : consequences for diagnosis and therapy

1 reference

12 December 2020

Glycoprotein IIb/IIIa antagonists--from bench to practice

1 reference

12 December 2020

Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors

1 reference

12 December 2020

No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors

1 reference

12 December 2020

Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties

1 reference

12 December 2020

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization

1 reference

12 December 2020

Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban.

1 reference

12 December 2020

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

12 December 2020

Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia

1 reference

12 December 2020

Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

1 reference

12 December 2020

Association of eptifibatide and acute profound thrombocytopenia

1 reference

12 December 2020

Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors

1 reference

12 December 2020

Immunofluorescent localization of adhesive glycoproteins in resting and thrombin-stimulated platelets

1 reference

12 December 2020

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention

1 reference

12 December 2020

Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment

1 reference

12 December 2020

Platelet activation and blood coagulation.

1 reference

12 December 2020

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention

1 reference

12 December 2020

Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up

1 reference

12 December 2020

The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2).

1 reference

12 December 2020

Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets

1 reference

12 December 2020

Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects

1 reference

12 December 2020

Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists

1 reference

12 December 2020

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

1 reference

12 December 2020

Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes

1 reference

12 December 2020

Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling

1 reference

12 December 2020

Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions

1 reference

12 December 2020

Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban

1 reference

12 December 2020

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

12 December 2020

Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists

1 reference

12 December 2020

Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation

1 reference

12 December 2020

Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo

1 reference

12 December 2020

Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention

1 reference

12 December 2020

Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).

1 reference

12 December 2020

Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa

1 reference

12 December 2020

Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation

1 reference

12 December 2020

Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction

1 reference

12 December 2020

Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy

1 reference

12 December 2020

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

1 reference

12 December 2020